Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Single cell transcriptomic analysis of prostate cancer cells.

Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, Gulati R, Larson SR, Lange PH, Montgomery B, Nelson PS, Vessella RL, Morrissey C.

BMC Mol Biol. 2013 Feb 16;14:6. doi: 10.1186/1471-2199-14-6.

2.

Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways.

Chéry L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, Montgomery B, Lange P, Snyder LA, Vessella RL, Morrissey C.

Oncotarget. 2014 Oct 30;5(20):9939-51.

3.

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.

Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, Pazzagli M, Di Leo A, Pinzani P.

Mol Oncol. 2015 Apr;9(4):749-57. doi: 10.1016/j.molonc.2014.12.001. Epub 2014 Dec 9.

4.

Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade.

Schmidt B, Anastasiadis AG, Seifert HH, Franke KH, Oya M, Ackermann R.

Anticancer Res. 2003 Sep-Oct;23(5A):3991-9.

PMID:
14666708
5.

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.

Chang K, Kong YY, Dai B, Ye DW, Qu YY, Wang Y, Jia ZW, Li GX.

Oncotarget. 2015 Dec 8;6(39):41825-36. doi: 10.18632/oncotarget.6167.

7.

Molecular phenotyping of circulating tumour cells in patients with prostate cancer: prediction of distant metastases.

Giesing M, Driesel G, Molitor D, Suchy B.

BJU Int. 2012 Dec;110(11 Pt C):E1202-11. doi: 10.1111/j.1464-410X.2012.11534.x. Epub 2012 Oct 9.

8.

Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.

Danila DC, Anand A, Schultz N, Heller G, Wan M, Sung CC, Dai C, Khanin R, Fleisher M, Lilja H, Scher HI.

Eur Urol. 2014 Jun;65(6):1191-7. doi: 10.1016/j.eururo.2013.07.006. Epub 2013 Jul 26.

9.

Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer.

Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpé S, Van Marck E, Vermeulen PB, Dirix LY.

Clin Breast Cancer. 2006 Jun;7(2):146-52.

PMID:
16800974
10.

Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines.

Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, Gretz N, Alken P, Michel MS.

Anticancer Res. 2005 Jan-Feb;25(1A):183-91.

11.

Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization.

Li X, Wong C, Mysel R, Slobodov G, Metwalli A, Kruska J, Manatt CS, Culkin DJ, Kropp BP, Lin HK.

Mol Cancer. 2005 Aug 8;4(1):30.

12.
14.

Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.

Pierga JY, Bonneton C, Magdelénat H, Vincent-Salomon A, Nos C, Boudou E, Pouillart P, Thiery JP, de Cremoux P.

Int J Cancer. 2005 Mar 20;114(2):291-8.

15.

Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.

Thomas C, Wiesner C, Melchior SW, Schmidt F, Gillitzer R, Thüroff JW, Pfitzenmaier J.

BJU Int. 2009 Jul;104(1):29-34. doi: 10.1111/j.1464-410X.2008.08298.x. Epub 2008 Dec 22.

16.

Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer.

Altintas DM, Allioli N, Decaussin M, de Bernard S, Ruffion A, Samarut J, Vlaeminck-Guillem V.

PLoS One. 2013 Jun 28;8(6):e66278. doi: 10.1371/journal.pone.0066278. Print 2013.

17.

Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR.

Strati A, Markou A, Parisi C, Politaki E, Mavroudis D, Georgoulias V, Lianidou E.

BMC Cancer. 2011 Oct 4;11:422. doi: 10.1186/1471-2407-11-422.

18.

Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients.

Breitenbuecher F, Hoffarth S, Worm K, Cortes-Incio D, Gauler TC, Köhler J, Herold T, Schmid KW, Freitag L, Kasper S, Schuler M.

PLoS One. 2014 Jan 21;9(1):e85350. doi: 10.1371/journal.pone.0085350. eCollection 2014.

19.

Amplification and overexpression of prosaposin in prostate cancer.

Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O.

Genes Chromosomes Cancer. 2005 Dec;44(4):351-64.

PMID:
16080200
20.

Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.

Neves RP, Raba K, Schmidt O, Honisch E, Meier-Stiegen F, Behrens B, Möhlendick B, Fehm T, Neubauer H, Klein CA, Polzer B, Sproll C, Fischer JC, Niederacher D, Stoecklein NH.

Clin Chem. 2014 Oct;60(10):1290-7. doi: 10.1373/clinchem.2014.222331.

Supplemental Content

Support Center